Table 1 Tafasitamab monotherapy vs L-mind regimen in NHL.
From: Diffuse large B-cell lymphoma: new targets and novel therapies
Number of patients | Overall response rate | Complete response rate | Median PFS (months) | Median DOR (months) | Reference | |
|---|---|---|---|---|---|---|
Tafasitamab single agent | 35 (DLBCL) | 26% | 6% | 2.7 | 20.1 | Jurczak22 |
34 (FL) | 29% | 9% | 8.8 | Not reached | ||
Lenalidomide single agent | 76 (FL) | 34.2% | 13.2% | 4.0 | 6.6 | Nowakowski25 |
Tafasitamab and lenalidomide | 81 (DLBCL) | 60% | 42.5% | 12.1 | 21.7 | Salles6 |
